Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

NCT03140722 is registered in ClinicalTrials.gov with Akebia Therapeutics as lead sponsor.

NCT NCT03140722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03140722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents
Lead sponsor
Akebia Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
May 2, 2017
Completion date
March 21, 2018
Enrollment
2 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, dialysis-dependent chronic kidney disease